Bausch + Lomb and Novaliq have completed enrollment in a second phase 3 study investigating NOV03 for the treatment of signs and symptoms of dry eye disease due to meibomian gland dysfunction, according to a press release.
The MOJAVE study will evaluate NOV03 (perfluorohexyloctane) in 622 subjects.
The first study, GOBI, met its primary and secondary endpoints. The phase 3 program also includes an ongoing multicenter, open-label, single-arm 12-month safety extension trial called KALAHARI.
“Completion of enrollment for the MOJAVE phase 3 study marks the next important milestone in our